You might also like
Inhibrx Biosciences, Inc. (INBX) is a clinical-stage biopharmaceutical company specializing in the development of innovative biologic therapeutic candidates. The company utilizes proprietary modular protein engineering platforms to create therapies with enhanced attributes and mechanisms, targeting challenging and validated disease areas. INBX's primary focus is on advancing its oncology pipeline, with a goal of addressing unmet medical needs and transitioning into a commercial-stage biopharmaceutical company.
-
INBRX-109 - A tetravalent death receptor 5 (DR5) agonist under investigation for treating various cancers, including colorectal and gastric adenocarcinomas, malignant pleural mesothelioma, chondrosarcoma, synovial sarcoma, Ewing sarcoma, and pancreatic adenocarcinoma. It has received orphan drug designation for unresectable or metastatic conventional chondrosarcoma.
-
INBRX-106 - A hexavalent OX40 agonist being studied in patients with non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
-
License Fee Revenue - Generates income through licensing agreements for its proprietary technologies and therapeutic candidates.
-
Grant Revenue - Previously recognized revenue from grants, such as a completed grant with the Department of Defense, though no grant revenue was recorded in the most recent period.